Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Severe chikungunya requiring intensive care in two travellers returning to the UK.

Calderwood C, Bhagani S, Cropley I, Papineni P.

J Travel Med. 2019 May 8. pii: taz033. doi: 10.1093/jtm/taz033. [Epub ahead of print] No abstract available.

PMID:
31066458
2.

A Typical Presentation of Tuberculosis in Cirrhosis.

Gananandan K, Cropley I, Westbrook R.

Clin Gastroenterol Hepatol. 2018 Aug 1. pii: S1542-3565(18)30799-7. doi: 10.1016/j.cgh.2018.07.034. [Epub ahead of print] No abstract available.

PMID:
30077034
3.

Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results.

Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S, Hopkins S, Seneviratne S, Cropley I, Lipman M.

Eur Respir J. 2017 Oct 26;50(4). pii: 1701267. doi: 10.1183/13993003.01267-2017. Print 2017 Oct. No abstract available.

4.

An association between pulmonary Mycobacterium avium-intracellulare complex infections and biomarkers of Th2-type inflammation.

Pfeffer PE, Hopkins S, Cropley I, Lowe DM, Lipman M.

Respir Res. 2017 May 15;18(1):93. doi: 10.1186/s12931-017-0579-9.

5.

Febrile illness in healthcare workers caring for Ebola virus disease patients in a high-resource setting.

Fink D, Cropley I, Jacobs M, Mepham S.

Euro Surveill. 2017 Jan 26;22(4). pii: 30449. doi: 10.2807/1560-7917.ES.2017.22.4.30449.

6.

Occupational Tuberculosis despite Minimal Nosocomial Contact in a Health Care Worker Undergoing Treatment with a Tumor Necrosis Factor Inhibitor.

Murphy ME, Wilmore S, Satta G, Witney A, Atzeni A, Sturgeon K, Cropley I, McHugh TD, Hopkins S, Lipman M.

Ann Am Thorac Soc. 2016 Dec;13(12):2275-2277. No abstract available.

PMID:
27925777
7.

Gallstone mimicry: a rare cause of abdominal pain.

Singh A, Smith PJ, Cropley IM, Planche KL, Hamilton MI, Murray CD.

Gut. 2017 Jul;66(7):1251. doi: 10.1136/gutjnl-2016-312706. Epub 2016 Sep 29. No abstract available.

PMID:
27686094
8.

Variation in C - reactive protein response according to host and mycobacterial characteristics in active tuberculosis.

Brown J, Clark K, Smith C, Hopwood J, Lynard O, Toolan M, Creer D, Barker J, Breen R, Brown T, Cropley I, Lipman M.

BMC Infect Dis. 2016 Jun 10;16:265. doi: 10.1186/s12879-016-1612-1.

9.

Late Ebola virus relapse causing meningoencephalitis: a case report.

Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC.

Lancet. 2016 Jul 30;388(10043):498-503. doi: 10.1016/S0140-6736(16)30386-5. Epub 2016 May 18.

10.

Ebola virus disease: the UK critical care perspective.

Martin D, Howard J, Agarwal B, Rajalingam Y, Athan B, Bhagani S, Cropley I, Hopkins S, Mepham S, Rodger A, Warren S, Jacobs M.

Br J Anaesth. 2016 May;116(5):590-6. doi: 10.1093/bja/aew098. Review.

11.

Zika virus.

Basarab M, Bowman C, Aarons EJ, Cropley I.

BMJ. 2016 Feb 26;352:i1049. doi: 10.1136/bmj.i1049. Review. No abstract available.

PMID:
26921241
12.

Thromboelastography in the Management of Coagulopathy Associated With Ebola Virus Disease.

Wilson AJ, Martin DS, Maddox V, Rattenbury S, Bland D, Bhagani S, Cropley I, Hopkins S, Mepham S, Rodger A, Warren S, Chowdary P, Jacobs M.

Clin Infect Dis. 2016 Mar 1;62(5):610-612. doi: 10.1093/cid/civ977. Epub 2015 Nov 26.

PMID:
26611775
13.

Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.

Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A.

Lancet Infect Dis. 2015 Nov;15(11):1300-4. doi: 10.1016/S1473-3099(15)00228-5. Epub 2015 Aug 25.

PMID:
26321189
14.

Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area.

Capocci S, Smith C, Morris S, Bhagani S, Cropley I, Abubakar I, Johnson M, Lipman M.

Eur Respir J. 2015 Jul;46(1):165-74. doi: 10.1183/09031936.00067114. Epub 2015 Apr 16.

15.

Expanded blood borne virus testing in a tuberculosis clinic. A cost and yield analysis.

Sewell J, Capocci S, Johnson J, Solamalai A, Hopkins S, Cropley I, Webster DP, Lipman M.

J Infect. 2015 Apr;70(4):317-23. doi: 10.1016/j.jinf.2014.10.014. Epub 2014 Nov 5.

PMID:
25452045
16.

Ebola virus disease: where are we now and where do we go?

Brown CS, Cropley IM.

Postgrad Med J. 2014 Nov;90(1069):610-2. doi: 10.1136/postgradmedj-2014-133068. No abstract available.

PMID:
25335794
17.

First confirmed case of Crimean-Congo haemorrhagic fever in the UK.

Barr DA, Aitken C, Bell DJ, Brown CS, Cropley I, Dawood N, Hopkins S, Jacobs M, Jeffs B, MacConnachie A, Mulvaney DW, Nicol E, Fox R.

Lancet. 2013 Oct 26;382(9902):1458. doi: 10.1016/S0140-6736(13)61718-3. Epub 2013 Oct 25. No abstract available.

PMID:
24243135
18.

Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?

Melchionda V, Wyatt H, Capocci S, Garcia Medina R, Solamalai A, Katiri S, Hopkins S, Cropley I, Lipman M.

Eur Respir J. 2013 Oct;42(4):1148-50. doi: 10.1183/09031936.00184312. No abstract available.

19.

An important diagnosis to consider in recurrent meningitis.

Verma N, Savy LE, Lund VJ, Cropley I, Chee R, Seneviratne SL.

JRSM Short Rep. 2013 Jul 30;4(9):2042533313486640. doi: 10.1177/2042533313486640. eCollection 2013. No abstract available.

20.

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7).

Draz N, Datta S, Webster DP, Cropley I.

BMJ Case Rep. 2013 Jul 31;2013. pii: bcr2013010348. doi: 10.1136/bcr-2013-010348.

21.

The value of "inform and advise" guidance in a case of extensive tuberculosis transmission.

Kumar K, Shorten RJ, Capocci S, Solamalai A, Goodburn A, Cropley I, McHugh TD, Lipman M.

J Infect. 2013 Aug;67(2):158-60. doi: 10.1016/j.jinf.2013.04.005. Epub 2013 Apr 13. No abstract available.

PMID:
23588105
22.

No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.

Singh R, Marshall N, Smith CJ, Reynolds CJ, Breen RA, Bhagani S, Cropley I, Hopkins S, Swaden L, Johnson MA, Lipman MC.

AIDS. 2013 Jan 28;27(3):481-4. doi: 10.1097/QAD.0b013e32835a67fb.

PMID:
23014518
23.

Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF╬▒ therapy.

Greveson K, Goodhand J, Capocci S, Woodward S, Murray C, Cropley I, Hamilton M, Lipman M.

J Crohns Colitis. 2013 Jun;7(5):412-8. doi: 10.1016/j.crohns.2012.08.010. Epub 2012 Sep 24.

PMID:
23009739
24.

Endogenous endophthalmitis and liver abscesses.

Koay S, Jain S, Cropley I, Petrushkin H, Beynon H.

Acute Med. 2012;11(1):25-7.

PMID:
22423344
25.

Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens.

Roberts CH, Smith C, Breen R, Gadhok R, Murphy M, Aryee A, Cropley I, Bhagani S, Hopkins S, Lipman M.

Int J Tuberc Lung Dis. 2011 Sep;15(9):1275-6. doi: 10.5588/ijtld.11.0352. No abstract available.

PMID:
21943863
26.

Citrobacter koseri meningitis: another freediving risk?

Pollara G, Savy L, Cropley I, Hopkins S.

J Infect. 2011 Jan;62(1):101-3. doi: 10.1016/j.jinf.2010.09.036. Epub 2010 Oct 7.

PMID:
20933000
27.

Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?

Walker NF, Kliner M, Turner D, Bhagani S, Cropley I, Hopkins S, Lipman M.

Thorax. 2009 Oct;64(10):918. doi: 10.1136/thx.2009.115469. No abstract available.

PMID:
19786720
28.

Westermark's sign in submassive pulmonary embolism.

Booth JW, Rakhit RD, Cropley I, Hurst JR.

Emerg Med J. 2009 Apr;26(4):282. doi: 10.1136/emj.2008.060087. No abstract available.

PMID:
19307391
29.

How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis?

Breen RA, Leonard O, Perrin FM, Smith CJ, Bhagani S, Cropley I, Lipman MC.

Int J Tuberc Lung Dis. 2008 Jan;12(1):44-9.

PMID:
18173876
30.

Rapid diagnosis of smear-negative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals.

Breen RA, Hardy GA, Perrin FM, Lear S, Kinloch S, Smith CJ, Cropley I, Janossy G, Lipman MC.

PLoS One. 2007 Dec 19;2(12):e1335.

31.

Clinical application of a rapid lung-orientated immunoassay in individuals with possible tuberculosis.

Breen RA, Barry SM, Smith CJ, Shorten RJ, Dilworth JP, Cropley I, McHugh TD, Gillespie SH, Janossy G, Lipman MC.

Thorax. 2008 Jan;63(1):67-71. Epub 2007 Aug 3.

PMID:
17675319
32.

Fever and haemoptysis in an injecting drug user.

Tan LK, Powrie DJ, Rowland R, Cropley I, Lipman M.

Eur Respir J. 2007 May;29(5):1061-3. No abstract available.

33.

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.

Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, Lipman MC.

Thorax. 2006 Sep;61(9):791-4. Epub 2006 Jul 14.

34.

Detection of mycobacterial antigen responses in lung but not blood in HIV-tuberculosis co-infected subjects.

Breen RA, Janossy G, Barry SM, Cropley I, Johnson MA, Lipman MC.

AIDS. 2006 Jun 12;20(9):1330-2.

PMID:
16816564
35.

Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.

Breen RA, Miller RF, Gorsuch T, Smith CJ, Ainsworth J, Ballinger J, Swaden L, Cropley I, Johnson MA, Lipman MC.

J Infect Dis. 2006 May 15;193(10):1437-40. Epub 2006 Apr 4.

PMID:
16619192
36.

HIV testing in TB clinics: a problem in practice?

Dart S, Alder D, Mamdani M, Solamalai A, Evans A, Johnson N, Cropley I, Lipman M.

Thorax. 2006 Mar;61(3):271-2. No abstract available.

37.

Endometrial tuberculosis presenting with deep vein thrombosis and pelvic mass mimicking a pelvic malignancy.

Bhalla R, Crow J, Bell J, Cropley I, Walker P.

J Obstet Gynaecol. 2005 Jul;25(5):517-8. No abstract available.

PMID:
16183600
38.

Local IFN-{gamma} responses in TB.

Breen RA, Hopkins S, Janossy G, Lipman MC, Cropley I.

Thorax. 2005 Sep;60(9):788-9. No abstract available.

39.

Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?

Breen RA, Smith CJ, Cropley I, Johnson MA, Lipman MC.

AIDS. 2005 Jul 22;19(11):1201-6.

PMID:
15990574
40.

The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens.

Colette JS, Sabin CA, Lampe FC, Shah S, Tyrer M, Youle MS, Cropley I, Johnson MA, Phillips AN.

Antivir Ther. 2005;10(3):459-67.

PMID:
15918337
41.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.

J Infect Dis. 2004 Nov 15;190(10):1860-8. Epub 2004 Oct 8.

PMID:
15499544
42.

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.

Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, Zhang HT, Price D, Phillips R, Weber J.

AIDS. 2002 Oct 18;16(15):2049-54.

PMID:
12370504
43.

Rapid diagnosis of Falciparum malaria by using the ParaSight F test in travellers returning to the United Kingdom: prospective study.

Cropley IM, Lockwood DN, Mack D, Pasvol G, Davidson RN.

BMJ. 2000 Aug 19-26;321(7259):484-5. No abstract available.

44.

Hepatitis C virus infection: co-infection with HIV and HBV.

Cropley I, Main J.

Baillieres Best Pract Res Clin Gastroenterol. 2000 Apr;14(2):265-75. Review.

PMID:
10890321
45.

Tuberculosis diagnosed during pregnancy: a prospective study from London.

Llewelyn M, Cropley I, Wilkinson RJ, Davidson RN.

Thorax. 2000 Feb;55(2):129-32.

46.

Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis.

Whitehead TC, Lovering AM, Cropley IM, Wade P, Davidson RN.

Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):794-7.

PMID:
9923523
47.

Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.

Cropley I, Douce G, Roberts M, Chatfield S, Pizza M, Marsili I, Rappuoli R, Dougan G.

Vaccine. 1995 Dec;13(17):1643-8.

PMID:
8719514
48.

Immunisation against Japanese encephalitis.

Bonington A, Harbord M, Davidson RN, Cropley I, Behrens RH.

Lancet. 1995 Jun 3;345(8962):1445-6. No abstract available.

PMID:
7760642
49.

A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Roberts M, Bacon A, Rappuoli R, Pizza M, Cropley I, Douce G, Dougan G, Marinaro M, McGhee J, Chatfield S.

Infect Immun. 1995 Jun;63(6):2100-8.

50.

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.

Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappuoli R, Dougan G.

Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1644-8.

Supplemental Content

Loading ...
Support Center